KRAS let-7 LCS6 SNP predicts cetuximab efficacy in KRASwt metastatic colorectal cancer patients: Does treatment combination partner matter?

Annals of Oncology

Volumn 22, Issue 2, 2011, Pages 484-485

  Zhang, W ^a   LaBonte, M J ^a   Lenz, H J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CETUXIMAB; IRINOTECAN; K RAS PROTEIN;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENOTYPE; HUMAN; LETTER; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

EID: 79251536545     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq704     Document Type: Letter

References (6)

1. Graziano F, Canestrari E, Loupakis F et al. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. Pharmacogenomics J 2010; 10: 458-464.
2. Ruzzo A, Canestrari E, Galluccio N et al. Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients. Ann Oncol 2011; 22: 234-235.
3. De Roock W, Claes B, Bernasconi D et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-762.
4. Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-5712.
5. Loupakis F, Ruzzo A, Cremolini C et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009; 101: 715-721.
6. Richman SD, Seymour MT, Chambers P et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27: 5931-5937.